Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...

A SYSTEMATIC review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded ...

For some, the issue with GLP-1 drugs like Ozempic and Mounjaro isn't getting access to these game-changing medications, but ...

Nearly half of individuals consuming alcohol at baseline reduced their alcohol consumption following the initiation of AOMs.

A new study suggests that popular weight loss drugs may reduce the risk of suicide in adolescents. KYW medical editor Dr. Brian McDonough has more.

Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...

The medication’s primary mechanism involves mimicking glucagon-like peptide-1 (GLP-1), a naturally occurring hormone in the ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...